2013 Pharmacogenomics mTOR.pdf

2018-04-09T14:31:59Z (GMT) by Gaetano Santulli Hana Totaryjain
p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Times; min-height: 14.0px} p.p2 {margin: 6.0px 0.0px 0.0px 0.0px; text-align: justify; line-height: 10.1px; font: 10.0px Times; color: #2c2728} span.s1 {font: 12.0px Times; color: #000000} <p>The mTOR signaling pathway integrates inputs from a variety of upstream stimuli to regulate diverse cellular processes including proliferation, growth, survival, motility, autophagy, protein synthesis and metabolism. The mTOR pathway is dysregulated in a number of human pathologies including cancer, diabetes, obesity, autoimmune disorders, neurological disease and aging. Ongoing clinical trials testing mTOR-targeted treatments number in the hundreds and underscore its therapeutic potential. To date mTOR inhibitors are clinically approved to prevent organ rejection, to inhibit restenosis after angioplasty, and to treat several advanced cancers. In this review we discuss the continuously evolving field of mTOR pharmacogenomics, as well as highlight the emerging efforts in identifying diagnostic and prognostic markers, including miRNAs, in order to assess successful therapeutic responses. <br></p>




CC BY 4.0